DDInter1608 DDInter1676
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences, [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab).
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Rituximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Rituximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Golimumab
Rituximab {u} may lead to a major life threatening interaction when taken with {v} Infliximab
Rituximab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Rituximab may lead to a major life threatening interaction when taken with Golimumab
Rituximab may lead to a major life threatening interaction when taken with Infliximab